depemokimab-ulaa (Exdensur)
depemokimab-ulaa is an FDA-licensed reference biologic from GlaxoSmithKline LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Exdensur depemokimab-ulaa
GlaxoSmithKline LLC
- Approved
- Dec 16, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for depemokimab-ulaa from the RCSB Protein Data Bank (PDB 9GVN).
Interactive biological assembly from PDB entry 9GVN. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for depemokimab-ulaa, in chronological order.
Reference approval
Approval date of the reference depemokimab-ulaa product.
6 mo ago
Frequently asked questions
Are there biosimilars approved for depemokimab-ulaa (Exdensur)?
No 351(k) biosimilars or interchangeable biosimilars referencing depemokimab-ulaa are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.